Effects of KB-5492, 1-(3,4,5-Trimethoxybenzyl)-4-((4-Methoxyphenyl)oxycarbonylmethyl)piperazine Monofumarate Monohydrate, on Gastric Lesions and Gastric Secretion in Rats | Zendy

Koichi Shimohara | Zendy; Hiromichi Niida | Zendy; Susumu Okabe | Zendy

Open Access

Effects of KB-5492, 1-(3,4,5-Trimethoxybenzyl)-4-((4-Methoxyphenyl)oxycarbonylmethyl)piperazine Monofumarate Monohydrate, on Gastric Lesions and Gastric Secretion in Rats

Author(s) -

Koichi Shimohara,

Hiromichi Niida,

Susumu Okabe

Publication year - 1990

Publication title -

the japanese journal of pharmacology

Language(s) - English

Resource type - Journals

eISSN - 1347-3506

pISSN - 0021-5198

DOI - 10.1254/jjp.53.275

Subject(s) - ed50 , gastric acid , gastric secretion , aspirin , secretion , histamine , chemistry , pharmacology , prednisolone , piperazine , drug , medicine , endocrinology , biochemistry , in vitro

Effects of a newly synthesized compound, KB-5492, on gastric lesions and gastric secretion were studied in rats. Oral KB-5492 inhibited the lesions induced by HCl.ethanol, HCl.aspirin, water-immersion stress, indomethacin, histamine and prednisolone at 30-300 mg/kg. The ED50 values varied from about 35 to 98 mg/kg. KB-5492 had no effect on gastric acid secretion even at 300 mg/kg. KB-5492 appeared to have a much more potent protective effect than a known anti-ulcer drug, sofalcone, against acute gastric lesions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research